Immunotherapeutic approaches for the treatment of malignant melanoma

Clara N Curiel, M. B. Atkins

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Clinical and laboratory observations suggest that host immunological responses may occassionally influence the course of melanoma, stimulating the investigation of immunotherapy approaches in this disease. Areas of active investigation have included recombinant cytokines, either alone or in combination with chemotherapeutic regimens or other biological response modifiers, such as vaccines, monoclonal antibodies, dendritic cells and gene therapy. To date, the benefit of these approaches in patients at high-risk of recurrence or advanced disease has been modest. Although many of these novel strategies are limited by weak antigen presentation, tumor-induced tolerance and tumor heterogeneity, it is possible that these approaches will prove more useful when given in combination.

Original languageEnglish (US)
Pages (from-to)1553-1563
Number of pages11
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number11
StatePublished - 2001
Externally publishedYes

Fingerprint

Melanoma
Antigen Presentation
Immunologic Factors
Cell- and Tissue-Based Therapy
Genetic Therapy
Immunotherapy
Dendritic Cells
Neoplasms
Vaccines
Monoclonal Antibodies
Cytokines
Recurrence
Therapeutics

Keywords

  • IFNα
  • IL-2
  • Immunotherapy
  • Malignant melanoma
  • Monoclonal antibody
  • Vaccines

ASJC Scopus subject areas

  • Pharmacology

Cite this

Immunotherapeutic approaches for the treatment of malignant melanoma. / Curiel, Clara N; Atkins, M. B.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 11, 2001, p. 1553-1563.

Research output: Contribution to journalArticle

@article{15850be964aa493887842cba421a1905,
title = "Immunotherapeutic approaches for the treatment of malignant melanoma",
abstract = "Clinical and laboratory observations suggest that host immunological responses may occassionally influence the course of melanoma, stimulating the investigation of immunotherapy approaches in this disease. Areas of active investigation have included recombinant cytokines, either alone or in combination with chemotherapeutic regimens or other biological response modifiers, such as vaccines, monoclonal antibodies, dendritic cells and gene therapy. To date, the benefit of these approaches in patients at high-risk of recurrence or advanced disease has been modest. Although many of these novel strategies are limited by weak antigen presentation, tumor-induced tolerance and tumor heterogeneity, it is possible that these approaches will prove more useful when given in combination.",
keywords = "IFNα, IL-2, Immunotherapy, Malignant melanoma, Monoclonal antibody, Vaccines",
author = "Curiel, {Clara N} and Atkins, {M. B.}",
year = "2001",
language = "English (US)",
volume = "2",
pages = "1553--1563",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Immunotherapeutic approaches for the treatment of malignant melanoma

AU - Curiel, Clara N

AU - Atkins, M. B.

PY - 2001

Y1 - 2001

N2 - Clinical and laboratory observations suggest that host immunological responses may occassionally influence the course of melanoma, stimulating the investigation of immunotherapy approaches in this disease. Areas of active investigation have included recombinant cytokines, either alone or in combination with chemotherapeutic regimens or other biological response modifiers, such as vaccines, monoclonal antibodies, dendritic cells and gene therapy. To date, the benefit of these approaches in patients at high-risk of recurrence or advanced disease has been modest. Although many of these novel strategies are limited by weak antigen presentation, tumor-induced tolerance and tumor heterogeneity, it is possible that these approaches will prove more useful when given in combination.

AB - Clinical and laboratory observations suggest that host immunological responses may occassionally influence the course of melanoma, stimulating the investigation of immunotherapy approaches in this disease. Areas of active investigation have included recombinant cytokines, either alone or in combination with chemotherapeutic regimens or other biological response modifiers, such as vaccines, monoclonal antibodies, dendritic cells and gene therapy. To date, the benefit of these approaches in patients at high-risk of recurrence or advanced disease has been modest. Although many of these novel strategies are limited by weak antigen presentation, tumor-induced tolerance and tumor heterogeneity, it is possible that these approaches will prove more useful when given in combination.

KW - IFNα

KW - IL-2

KW - Immunotherapy

KW - Malignant melanoma

KW - Monoclonal antibody

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=0035182099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035182099&partnerID=8YFLogxK

M3 - Article

C2 - 11763157

AN - SCOPUS:0035182099

VL - 2

SP - 1553

EP - 1563

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 11

ER -